Background: Trimodality therapy (TMT) for EC is associated with significant toxicity. Limited data are available on the safety of nCRT in vulnerable populations such as older pts. We evaluated the associations between age and toxicity as well as survival in pts treated with nCRT as part of TMT. Methods: A retrospective review of pts with EC treated with nCRT as part of TMT at an academic cancer center between 2002-2014 was conducted. We assessed the impact of age (<65 versus ≥65) on chemotherapy dose reduction/interruption (DRI), hospitalizations (H), and toxicity including grade 3/4 (G3+T), and composite number of any grade non-hematologic (NHT) or hematologic (HT) toxicity. Relapse free (RFS) and overall survival (OS) were assessed with the Kaplan-Meier (KM) method. Univariate (UVA) and multivariate regression analyses (MVA) were performed. Results: 125 pts were identified. The median age was 63 (range 35-80) with 46% of patients ≥65.There were increased co-morbidities in older pts and more active smokers in younger group. Otherwise,baseline characteristics were well balanced. In UVA, advanced age was associated with increased HT, and a trend towards increased G3+T (table 1). After adjusting for covariates in MVA, no differences in toxicity were noted between older and younger pts. There were no differences in RFS or OS between groups (table).Conclusions: Our study demonstrates similar rates of toxicity and outcomes among older and younger EC patients treated with nCRT as part of TMT. Advanced age alone should not be a barrier to nCRT.